- Ironwood Pharmaceuticals (IRWD, Financial) shares surged by 9% premarket after revising core earnings projections above $105 million for 2025.
- Consensus from analysts sets the average price target at $5.12, with a potential upside of over 482.30%.
- GuruFocus estimates a significant upside of 725.08% based on their GF Value metric.
Ironwood Pharmaceuticals (IRWD) witnessed a robust 9% gain in premarket trading after announcing a revised core earnings projection surpassing $105 million for 2025. The company confidently reaffirmed its U.S. net sales target for LINZESS in 2025, ranging between $800 and $850 million, and expects total revenue between $260 million and $290 million.
Wall Street Analysts' Forecast
According to one-year price targets proposed by six analysts, the average target price for Ironwood Pharmaceuticals Inc (IRWD, Financial) is $5.12. This is set against a high estimate of $14.00 and a low estimate of $0.70. The average target suggests an impressive upside of 482.30% from the current trading price of $0.88. For more in-depth estimate data, please refer to the Ironwood Pharmaceuticals Inc (IRWD) Forecast page.
The consensus recommendation from seven brokerage firms assigns Ironwood Pharmaceuticals Inc (IRWD, Financial) an average brokerage recommendation of 2.6, indicating a "Hold" status. This rating scale ranges from 1 to 5, where 1 denotes a Strong Buy and 5 suggests a Sell.
GuruFocus Valuation Insights
According to GuruFocus estimates, the predicted GF Value for Ironwood Pharmaceuticals Inc (IRWD, Financial) in one year is $7.25. This estimate implies a substantial upside of 725.08% from the current valuation of $0.8787. The GF Value represents GuruFocus's calculation of the fair value at which the stock should ideally trade. This is determined through historical trading multiples, past business growth, and future business performance estimates. For detailed information, please visit the Ironwood Pharmaceuticals Inc (IRWD) Summary page.
